Filter articles using the following links

GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update

Mitochondria-Targeted Drug Development Summit, Digital

GenSight Biologics Announces the Filing of its 2020 Universal Registration Document

Annual General Meeting on April 29, 2021

GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors

GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

BioEurope Spring – virtual

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

2021 AAN Annual Meeting, virtual

Cell & Gene Meeting on the Mediterranean, virtual